We make healthcare
Understandable, Accessible and Affordable.

About Maven

Maven Bioscience stands at the forefront of the precision medicine revolution, transforming medical paradigms for both animals and humans through groundbreaking cannabinoid-derived treatments.

Since its establishment in 2017, Maven has pioneered a diversified revenue platform that includes supplying active pharmaceutical ingredients, bulk formulations, white-label manufacturing, and branded products across a global landscape, including the US, Japan, Mexico, Costa Rica, Ecuador, Brasil, and Australia.

Mavens Approach

The cornerstone of Maven’s approach lies in its commitment to science-based methodologies, rigorously validated through research. This strategic commitment has reshaped their therapeutic methodology, steering towards personalized medicine that leverages a patient’s DNA and metabolic profile, resulting in safer and more effective outcomes. This distinctive strategy

sets Maven apart from the conventional ‘one-size-fits-all’ approach prevalent in the US cannabinoid landscape.

Latin America

Over the past year, Maven’s products and services have experienced a surge in demand in Latin America, a region where the medical application of cannabinoids takes precedence over the recreational and dietary focus found in the US markets.

Science-Driven Platform

Maven’s science-driven platform not only differentiates it from its US competitors but also facilitates swift market entry into

countries such as Colombia, Mexico, Brasil, Ecuador, Costa Rica, Paraguay, Panama and Israel. The catalyst behind this rapid adoption is Maven’s strategic relationships, designed to meet Latin America’s demand for clinically proven cannabinoid products that prioritize safety and efficacy.